Address: V.le Fulvio Testi, 330, 20126 Milano,Italy
Tel: 02 64431
Web: http://www.italfarmaco.com/
Italfarmaco operates in both the pharmaceutical and the fine chemical industries and was founded in Milan in 1938.
The Italfarmaco Group now markets ethical products in Italy, Spain, Portugal and Greece, where it employs a workforce of over 1400 and has a total turnover exceeding 300 million euros.
The groups owns a plant in Milan, and a second in Madrid.
The Italfarmaco Group is particularly active in the field of research, mainly oriented towards the cardiovascular area and diseases associated with alterations of the immunological system.
In addition to its pharmaceutical activities in the field of ethical drugs, Italfarmaco also markets generic drugs through the company Lifepharma.
This business is mainly aimed at foreign markets, on some of which Lifepharma has its own offices and sales networks, as in the case of Russia.
In addition to research, production and marketing of drugs, the Italfarmaco Group manufactures active ingredients for the pharmaceutical industry through its subsidiary ‘Chemi S.p.A.’
Chemi S.p.A. sells some 90% of its products on foreign markets (USA, Japan, EU, etc.), on which it collaborates with many international pharmaceutical companies.
Its therapeuticals areas are mainly cardiovascular, immuno-oncological, gynaecological, dermatological, orthopaedic and neurological areas.
Equipped with a strong business acumen, Italfarmaco (ITF) Hellas’ Managing Director, Polly Leontaridis-Kalogera emphasizes the critical importance of the decision to focus on women’s health in building a resilient affiliate…
Italfarmaco counts amongst the few players who really sustained the growth of the Italian pharmaceutical industry in the past 10 years. Which specific values would you quote as keys to…
A roundup of some of the biggest stories from Italian pharma and healthcare, including Italfarmaco’s FDA approval for its DMD treatment; Alfasigma’s acquisition of Galapagos’s Jyseleca, the antibiotics deal between…
The grants and loans allocated by the European Union’s Recovery and Resilience Facility (RRF), a large part of which have been assigned to healthcare, set out to mitigate the economic…
After former CEO Pierluigi Antonelli abruptly announced his departure last month, the Italian mid-cap has signed on former Gilead leader, Jacopo Andreose, as its new chief executive. [I am]…
Angelini Pharma CEO Pierluigi Antonelli has announced that he is leaving his position with immediate effect, posing the question of what comes next for the leading Italian mid-cap. Antonelli,…
The electoral victory of the centre-right coalition in Italy should see far-right firebrand Giorgia Meloni replace former European Central Bank President Mario Draghi as Prime Minister at the end of…
Digitalisation has become a buzz word in in the global life sciences sector. In Italy, digital transformation has taken on special significance as one of the principal goals encompassed in…
The Italian system requires drug companies to go through approvals at a national level with the Italian Medicines Agency (AIFA), only to then confront the country’s 21 regional authorities who…
Historically, SIFI has been a modest local player focused on ophthalmic products, but in recent years the company has set some ambitious goals for itself—becoming a leading force in European…
Seasoned executive Pierluigi Antonelli went from a career in big pharma to Angelini Pharma, a midsized Italian company that has been undergoing major transformation. He shares the motivation behind the…
Collectively representing almost 400 companies operating in Italy, Farmindustria, Egualia (formerly Assogenerici) and Assobiotec respectively promote the interests of innovative pharmaceutical companies—both foreign and Italian-owned— the generics, biosimilars and value-added…
As the European Union’s largest beneficiary of the Next Generation EU (NGEU) package, aimed at boosting the EU’s economy following the COVID-19 pandemic, Italy will receive some EUR 235 billion…
While Italy’s biotech landscape is generally held to be somewhat immature in comparison to more established markets such as Germany, France or the UK, that does not imply a deficit…
See our Cookie Privacy Policy Here
